Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma.pdf (278.39 kB)Download file
Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma
journal contributionposted on 2021-02-17, 05:17 authored by Hui GanHui Gan
• Optimal use of phase II data may reduce chances of failure in subsequent phase III studies.
• Inappropriate utilization or a lack of phase II data appears to contribute to phase III failure.
• Only 35% of phase III trials in our review transitioned from phase II to III in an optimal manner.